Abstract Background Most current cardiovascular disease (CVD) prediction tools have been developed and validated solely in Western countries, while there are significant differences between Asian and Western populations in risk factor distributions and CVD incidence patterns. This study outlines the recalibration and validation of the SCORE2-ASIA model to estimate 10-year fatal and non-fatal CVD risk among adults aged 40-69 years with no previous CVD or diabetes in the Asia Pacific Region. Methods The sex-specific and competing risk-adjusted SCORE2 models were systematically recalibrated to reflect CVD incidence in the Asian clinical practice. We defined four risk regions in Asia according to country-specific CVD mortality rates (low risk (<100 CVD deaths per 100,000), moderate risk (100 to <150 CVD deaths per 100,000), high risk (150 to <300 CVD deaths per 100,000), and very high risk (≥300 CVD deaths per 100,000)). Models were recalibrated using region representative data on expected incidences and risk factor distributions, utilising the methodological approaches developed in recalibration of the SCORE2 models for Europe. The SCORE-ASIA model was externally validated in all risk regions using population-based cohort data from independents cohort data. To ensure the European coefficients well applied to Asian populations, the SCORE2 model derivation process was repeated in external validation cohorts. Results Region-specific incidence was estimated using country-specific data on CVD mortality and data on the ratio of fatal to total events on 9,496,212 individuals from 5 Asian countries (496,212 CVD events). For external validation, we analysed data from 12 additional cohorts in 13 Asian countries (4,775,976 individuals, 176,011 CVD events). After applying the derived risk prediction models to external validation cohorts, the pooled external validation C-index was 0.709 (95%CI 0.676-0.743). In the nationally representative CDMD cohort from Singapore (population completely separate from recalibration data) there was adequate agreement between predicted and observed risks. Risk factor coefficients derived in Asian populations were largely similar to the original SCORE2 coefficients, indicating that the original SCORE2 coefficients apply well to the Asian population. Predicted CVD risk varied several-fold across Asian risk regions. For example, the estimated 10-year CVD risk for a 50-year-old non-smoker, with a systolic blood pressure of 140mmHg, total cholesterol of 5.5mmol/L, and HDL-cholesterol of 1.3mmol/L, ranged from 12% for men in low-risk countries to 26% for men in very-high-risk countries, and from 7% for women in low-risk countries to 26% for women in very-high-risk countries. Conclusions The SCORE2-ASIA model accurately predicts 10-year risk of CVD for apparently healthy people in Asian countries after systematic recalibration, thereby enhancing the identification of individuals at higher risk of developing CVD across the Asia Pacific Region.